niacinamide has been researched along with Astrocytoma, Grade IV in 34 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We hypothesized that vertical blockade of VEGF signaling by combining bevacizumab with sorafenib in patients with recurrent glioblastoma would result in a synergistic therapeutic effect." | 9.17 | Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. ( Anderson, SK; Buckner, JC; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaufmann, TJ; Kimlinger, TK; Kumar, SK; Lafky, JM; Northfelt, DW; Uhm, JH, 2013) |
| "The current study was conducted to evaluate the efficacy of sorafenib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, when added to standard radiotherapy and temozolomide in the first-line treatment of patients with glioblastoma multiforme." | 9.14 | Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. ( Clark, BL; Ervin, T; Friedman, E; Hainsworth, JD; Lamar, RE; Murphy, PB; Priego, V, 2010) |
| "Prospective evaluation of the toxicity and efficacy of carbogen and nicotinamide with external beam radiotherapy in the management of inoperable glioblastoma." | 9.10 | Radiotherapy and chemotherapy with or without carbogen and nicotinamide in inoperable biopsy-proven glioblastoma multiforme. ( Baillet, F; Chiras, J; Delattre, JY; Hoang-Xuan, K; Mazeron, JJ; Noël, G; Simon, JM, 2003) |
| "A three-step phase I/II trial associating accelerated radiotherapy with carbogen (step 1, ARCO), with nicotinamide (step 2, ARN), or with both (step 3, ARCON) was conducted, the aim of which was to overcome the effects of proliferation and hypoxia as potential causes of tumor radioresistance in glioblastoma multiforme." | 9.09 | Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. ( Bernier, J; Bolla, M; Denekamp, J; Greiner, R; Hulshof, M; Miralbell, R; Mirimanoff, RO; Mornex, F; Pierart, M; Rojas, AM; Storme, G; van Glabbeke, M, 1999) |
| "Nineteen patients with glioblastoma were studied with 99mtechnetium-hexamethylpropyleneamine oxime single photon emission computed tomography (99mTc-HMPAO SPECT) before and after administration of carbogen and/or NAM." | 9.08 | Lack of perfusion enhancement after administration of nicotinamide and carbogen in patients with glioblastoma: a 99mTc-HMPAO SPECT study. ( Booij, J; Bosch, DA; González González, D; Hulshof, MC; Rehmann, CJ; van Royen, EA, 1998) |
| "Nineteen patients with glioblastoma were treated with nicotinamide and carbogen and radiotherapy." | 9.08 | Tolerance of nicotinamide and carbogen with radiation therapy for glioblastoma. ( Duncan, GG; Graham, P; Green, A; Marlow, C; Pickles, T; Rheaume, DE; Syndikus, I, 1996) |
| "The effect of sorafenib on signaling, proliferation, radiosensitivity, chemosensitivity and radiochemosensitivity was analyzed in six glioblastoma cell lines using Western blot, proliferation- and colony formation assays." | 7.83 | Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines. ( Dikomey, E; Köcher, S; Kriegs, M; Müller-Goebel, J; Petersen, C; Riedel, M; Rothkamm, K; Struve, N, 2016) |
| "The aim of the present study was to investigate the effect of sorafenib and quercetin on the induction of apoptosis and autophagy in human anaplastic astrocytoma (MOGGCCM) and glioblastoma multiforme (T98G) cell lines." | 7.80 | Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I, 2014) |
| "This study addressed the potential radiosensitizing effect of nicotinamide and/or carbogen on human glioblastoma xenografts in nude mice." | 7.71 | Fractionated irradiation combined with carbogen breathing and nicotinamide of two human glioblastomas grafted in nude mice. ( Buchegger, F; Coucke, PA; Mirimanoff, RO; Sun, LQ, 2001) |
| "A new radiotherapy schedule to treat glioblastoma multiforme after surgery, combining nicotinamide and carbogen." | 7.69 | Carbogen and nicotinamide combined with unconventional radiotherapy in glioblastoma multiforme: a new modality treatment. ( Caciagli, P; Cartei, F; Colosimo, S; Danesi, R; Del Tacca, M; Ducci, F; Fatigante, L; Laddaga, M; Marini, C; Prediletto, R, 1997) |
| " Pharmacokinetic sampling was performed during cycle 1." | 6.78 | NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. ( Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X, 2013) |
| " The maximum tolerated dosage (MTD) for combination therapy was sorafenib 800 mg daily and temsirolimus 25 mg once weekly." | 6.77 | Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. ( Abrey, L; Aldape, K; Chang, SM; Cloughesy, TF; Dancey, JE; DeAngelis, LM; Drappatz, J; Gilbert, MR; Kuhn, J; Lamborn, KR; Lee, EQ; Levin, VA; Lieberman, F; Mehta, MP; Prados, MD; Robins, HI; Wen, PY; Wright, JJ; Yung, WK, 2012) |
| " In addition, various protracted temozolomide dosing schedules have been evaluated as a strategy to further enhance its anti-tumor activity." | 6.76 | Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011) |
| "Glioblastomas are grade IV brain tumors characterized by high aggressiveness and invasiveness, giving patients a poor prognosis." | 5.39 | Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. ( Barbieri, F; Carra, E; Daga, A; Favoni, RE; Florio, T; Marubbi, D; Pattarozzi, A, 2013) |
| "Glioblastoma is the most common type of primary brain tumor and is rapidly progressive with few treatment options." | 5.36 | Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. ( Brown, C; Buettner, R; Hedvat, M; Jensen, M; Jove, R; Schroeder, A; Scuto, A; Starr, R; Yang, F, 2010) |
| "We hypothesized that vertical blockade of VEGF signaling by combining bevacizumab with sorafenib in patients with recurrent glioblastoma would result in a synergistic therapeutic effect." | 5.17 | Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial. ( Anderson, SK; Buckner, JC; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaufmann, TJ; Kimlinger, TK; Kumar, SK; Lafky, JM; Northfelt, DW; Uhm, JH, 2013) |
| "The current study was conducted to evaluate the efficacy of sorafenib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, when added to standard radiotherapy and temozolomide in the first-line treatment of patients with glioblastoma multiforme." | 5.14 | Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. ( Clark, BL; Ervin, T; Friedman, E; Hainsworth, JD; Lamar, RE; Murphy, PB; Priego, V, 2010) |
| "Prospective evaluation of the toxicity and efficacy of carbogen and nicotinamide with external beam radiotherapy in the management of inoperable glioblastoma." | 5.10 | Radiotherapy and chemotherapy with or without carbogen and nicotinamide in inoperable biopsy-proven glioblastoma multiforme. ( Baillet, F; Chiras, J; Delattre, JY; Hoang-Xuan, K; Mazeron, JJ; Noël, G; Simon, JM, 2003) |
| "A three-step phase I/II trial associating accelerated radiotherapy with carbogen (step 1, ARCO), with nicotinamide (step 2, ARN), or with both (step 3, ARCON) was conducted, the aim of which was to overcome the effects of proliferation and hypoxia as potential causes of tumor radioresistance in glioblastoma multiforme." | 5.09 | Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. ( Bernier, J; Bolla, M; Denekamp, J; Greiner, R; Hulshof, M; Miralbell, R; Mirimanoff, RO; Mornex, F; Pierart, M; Rojas, AM; Storme, G; van Glabbeke, M, 1999) |
| "Nineteen patients with glioblastoma were treated with nicotinamide and carbogen and radiotherapy." | 5.08 | Tolerance of nicotinamide and carbogen with radiation therapy for glioblastoma. ( Duncan, GG; Graham, P; Green, A; Marlow, C; Pickles, T; Rheaume, DE; Syndikus, I, 1996) |
| "Nineteen patients with glioblastoma were studied with 99mtechnetium-hexamethylpropyleneamine oxime single photon emission computed tomography (99mTc-HMPAO SPECT) before and after administration of carbogen and/or NAM." | 5.08 | Lack of perfusion enhancement after administration of nicotinamide and carbogen in patients with glioblastoma: a 99mTc-HMPAO SPECT study. ( Booij, J; Bosch, DA; González González, D; Hulshof, MC; Rehmann, CJ; van Royen, EA, 1998) |
| "The effect of sorafenib on signaling, proliferation, radiosensitivity, chemosensitivity and radiochemosensitivity was analyzed in six glioblastoma cell lines using Western blot, proliferation- and colony formation assays." | 3.83 | Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines. ( Dikomey, E; Köcher, S; Kriegs, M; Müller-Goebel, J; Petersen, C; Riedel, M; Rothkamm, K; Struve, N, 2016) |
| "The aim of the present study was to investigate the effect of sorafenib and quercetin on the induction of apoptosis and autophagy in human anaplastic astrocytoma (MOGGCCM) and glioblastoma multiforme (T98G) cell lines." | 3.80 | Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas. ( Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I, 2014) |
| "This study addressed the potential radiosensitizing effect of nicotinamide and/or carbogen on human glioblastoma xenografts in nude mice." | 3.71 | Fractionated irradiation combined with carbogen breathing and nicotinamide of two human glioblastomas grafted in nude mice. ( Buchegger, F; Coucke, PA; Mirimanoff, RO; Sun, LQ, 2001) |
| "A new radiotherapy schedule to treat glioblastoma multiforme after surgery, combining nicotinamide and carbogen." | 3.69 | Carbogen and nicotinamide combined with unconventional radiotherapy in glioblastoma multiforme: a new modality treatment. ( Caciagli, P; Cartei, F; Colosimo, S; Danesi, R; Del Tacca, M; Ducci, F; Fatigante, L; Laddaga, M; Marini, C; Prediletto, R, 1997) |
| "Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may further act as a potent radiosensitizer by arresting cells in the most radiosensitive cell cycle phase." | 2.79 | Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. ( Ben Aissa, A; Bodmer, A; Dietrich, PY; Dunkel, N; Espeli, V; Hottinger, AF; Hundsberger, T; Mach, N; Schaller, K; Squiban, D; Vargas, MI; Weber, DC, 2014) |
| " Pharmacokinetic sampling was performed during cycle 1." | 2.78 | NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme. ( Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X, 2013) |
| " The maximum tolerated dosage (MTD) for combination therapy was sorafenib 800 mg daily and temsirolimus 25 mg once weekly." | 2.77 | Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. ( Abrey, L; Aldape, K; Chang, SM; Cloughesy, TF; Dancey, JE; DeAngelis, LM; Drappatz, J; Gilbert, MR; Kuhn, J; Lamborn, KR; Lee, EQ; Levin, VA; Lieberman, F; Mehta, MP; Prados, MD; Robins, HI; Wen, PY; Wright, JJ; Yung, WK, 2012) |
| " In addition, various protracted temozolomide dosing schedules have been evaluated as a strategy to further enhance its anti-tumor activity." | 2.76 | Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. ( Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ, 2011) |
| "Treatment of brain cancer cells with [sorafenib + lapatinib] enhanced radiation toxicity." | 1.42 | Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells. ( Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Tavallai, S, 2015) |
| "Glioblastomas are grade IV brain tumors characterized by high aggressiveness and invasiveness, giving patients a poor prognosis." | 1.39 | Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. ( Barbieri, F; Carra, E; Daga, A; Favoni, RE; Florio, T; Marubbi, D; Pattarozzi, A, 2013) |
| "Glioblastoma is the most common type of primary brain tumor and is rapidly progressive with few treatment options." | 1.36 | Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. ( Brown, C; Buettner, R; Hedvat, M; Jensen, M; Jove, R; Schroeder, A; Scuto, A; Starr, R; Yang, F, 2010) |
| "The pharmacokinetic properties of nicotinamide and its tolerance were studied in seven patients affected by glioblastoma multiforme and treated with two fractions per day of radiation therapy." | 1.29 | Pharmacokinetics and tolerance of nicotinamide combined with radiation therapy in patients with glioblastoma multiforme. ( Caciagli, PG; Cartei, F; Danesi, R; Ducci, F; Fatigante, L; Laddaga, M; Tacca, M, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.94) | 18.7374 |
| 1990's | 7 (20.59) | 18.2507 |
| 2000's | 2 (5.88) | 29.6817 |
| 2010's | 22 (64.71) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Varlamova, EG | 1 |
| Khabatova, VV | 1 |
| Gudkov, SV | 1 |
| Turovsky, EA | 1 |
| Clavreul, A | 1 |
| Pourbaghi-Masouleh, M | 1 |
| Roger, E | 1 |
| Lautram, N | 1 |
| Montero-Menei, CN | 1 |
| Menei, P | 1 |
| Abdel Gaber, SA | 1 |
| Müller, P | 1 |
| Zimmermann, W | 1 |
| Hüttenberger, D | 1 |
| Wittig, R | 1 |
| Abdel Kader, MH | 1 |
| Stepp, H | 1 |
| Marafi, F | 1 |
| Sasikumar, A | 1 |
| Fathallah, W | 1 |
| Esmail, A | 1 |
| Galanis, E | 1 |
| Anderson, SK | 1 |
| Lafky, JM | 1 |
| Uhm, JH | 1 |
| Giannini, C | 1 |
| Kumar, SK | 1 |
| Kimlinger, TK | 1 |
| Northfelt, DW | 1 |
| Flynn, PJ | 1 |
| Jaeckle, KA | 1 |
| Kaufmann, TJ | 1 |
| Buckner, JC | 1 |
| Zustovich, F | 2 |
| Landi, L | 1 |
| Lombardi, G | 2 |
| Porta, C | 1 |
| Galli, L | 1 |
| Fontana, A | 1 |
| Amoroso, D | 1 |
| Galli, C | 1 |
| Andreuccetti, M | 1 |
| Falcone, A | 1 |
| Zagonel, V | 2 |
| Jakubowicz-Gil, J | 1 |
| Langner, E | 1 |
| Bądziul, D | 1 |
| Wertel, I | 1 |
| Rzeski, W | 1 |
| Sabancι, PA | 1 |
| Ergüven, M | 1 |
| Yazιhan, N | 1 |
| Aktaş, E | 1 |
| Aras, Y | 1 |
| Civelek, E | 1 |
| Aydoseli, A | 1 |
| Imer, M | 1 |
| Gürtekin, M | 1 |
| Bilir, A | 1 |
| Hottinger, AF | 1 |
| Ben Aissa, A | 1 |
| Espeli, V | 1 |
| Squiban, D | 1 |
| Dunkel, N | 1 |
| Vargas, MI | 1 |
| Hundsberger, T | 1 |
| Mach, N | 1 |
| Schaller, K | 1 |
| Weber, DC | 1 |
| Bodmer, A | 1 |
| Dietrich, PY | 1 |
| Hamed, HA | 1 |
| Tavallai, S | 1 |
| Grant, S | 1 |
| Poklepovic, A | 1 |
| Dent, P | 1 |
| Ferrandon, S | 1 |
| Malleval, C | 1 |
| El Hamdani, B | 1 |
| Battiston-Montagne, P | 1 |
| Bolbos, R | 1 |
| Langlois, JB | 1 |
| Manas, P | 1 |
| Gryaznov, SM | 1 |
| Alphonse, G | 1 |
| Honnorat, J | 1 |
| Rodriguez-Lafrasse, C | 1 |
| Poncet, D | 1 |
| Liu, X | 1 |
| Sun, K | 1 |
| Wang, H | 1 |
| Dai, Y | 1 |
| Bell, JB | 1 |
| Eckerdt, FD | 1 |
| Alley, K | 1 |
| Magnusson, LP | 1 |
| Hussain, H | 1 |
| Bi, Y | 1 |
| Arslan, AD | 1 |
| Clymer, J | 1 |
| Alvarez, AA | 1 |
| Goldman, S | 1 |
| Cheng, SY | 1 |
| Nakano, I | 1 |
| Horbinski, C | 1 |
| Davuluri, RV | 1 |
| James, CD | 1 |
| Platanias, LC | 1 |
| Riedel, M | 1 |
| Struve, N | 1 |
| Müller-Goebel, J | 1 |
| Köcher, S | 1 |
| Petersen, C | 1 |
| Dikomey, E | 1 |
| Rothkamm, K | 1 |
| Kriegs, M | 1 |
| Hofstetter, CP | 1 |
| Boockvar, JA | 1 |
| Yang, F | 1 |
| Brown, C | 1 |
| Buettner, R | 1 |
| Hedvat, M | 1 |
| Starr, R | 1 |
| Scuto, A | 1 |
| Schroeder, A | 1 |
| Jensen, M | 1 |
| Jove, R | 1 |
| Reardon, DA | 1 |
| Vredenburgh, JJ | 1 |
| Desjardins, A | 1 |
| Peters, K | 1 |
| Gururangan, S | 1 |
| Sampson, JH | 1 |
| Marcello, J | 1 |
| Herndon, JE | 1 |
| McLendon, RE | 1 |
| Janney, D | 1 |
| Friedman, AH | 1 |
| Bigner, DD | 1 |
| Friedman, HS | 1 |
| Rokes, CA | 1 |
| Remke, M | 1 |
| Guha-Thakurta, N | 1 |
| Witt, O | 1 |
| Korshunov, A | 1 |
| Pfister, S | 1 |
| Wolff, JE | 1 |
| Siegelin, MD | 1 |
| Raskett, CM | 1 |
| Gilbert, CA | 1 |
| Ross, AH | 1 |
| Altieri, DC | 1 |
| Hainsworth, JD | 1 |
| Ervin, T | 1 |
| Friedman, E | 1 |
| Priego, V | 1 |
| Murphy, PB | 1 |
| Clark, BL | 1 |
| Lamar, RE | 1 |
| Farina, P | 1 |
| Fiduccia, P | 1 |
| Della Puppa, A | 1 |
| Polo, V | 1 |
| Bertorelle, R | 1 |
| Gardiman, MP | 1 |
| Banzato, A | 1 |
| Ciccarino, P | 1 |
| Denaro, L | 1 |
| Lee, EQ | 1 |
| Kuhn, J | 1 |
| Lamborn, KR | 1 |
| Abrey, L | 1 |
| DeAngelis, LM | 1 |
| Lieberman, F | 1 |
| Robins, HI | 1 |
| Chang, SM | 1 |
| Yung, WK | 1 |
| Drappatz, J | 1 |
| Mehta, MP | 1 |
| Levin, VA | 1 |
| Aldape, K | 1 |
| Dancey, JE | 1 |
| Wright, JJ | 1 |
| Prados, MD | 1 |
| Cloughesy, TF | 1 |
| Gilbert, MR | 1 |
| Wen, PY | 1 |
| Carra, E | 1 |
| Barbieri, F | 1 |
| Marubbi, D | 1 |
| Pattarozzi, A | 1 |
| Favoni, RE | 1 |
| Florio, T | 1 |
| Daga, A | 1 |
| Peereboom, DM | 1 |
| Ahluwalia, MS | 1 |
| Ye, X | 1 |
| Supko, JG | 1 |
| Hilderbrand, SL | 1 |
| Phuphanich, S | 1 |
| Nabors, LB | 1 |
| Rosenfeld, MR | 1 |
| Mikkelsen, T | 1 |
| Grossman, SA | 1 |
| Simon, JM | 1 |
| Noël, G | 1 |
| Chiras, J | 1 |
| Hoang-Xuan, K | 1 |
| Delattre, JY | 1 |
| Baillet, F | 1 |
| Mazeron, JJ | 1 |
| Cartei, F | 2 |
| Danesi, R | 2 |
| Ducci, F | 2 |
| Fatigante, L | 2 |
| Caciagli, PG | 1 |
| Tacca, M | 1 |
| Laddaga, M | 2 |
| Pickles, T | 1 |
| Graham, P | 1 |
| Syndikus, I | 1 |
| Rheaume, DE | 1 |
| Duncan, GG | 1 |
| Green, A | 1 |
| Marlow, C | 1 |
| Colosimo, S | 1 |
| Marini, C | 1 |
| Prediletto, R | 1 |
| Del Tacca, M | 1 |
| Caciagli, P | 1 |
| Horsman, MR | 2 |
| Stüben, G | 1 |
| Stuschke, M | 1 |
| Knühmann, K | 1 |
| Sack, H | 1 |
| Hulshof, MC | 1 |
| Rehmann, CJ | 1 |
| Booij, J | 1 |
| van Royen, EA | 1 |
| Bosch, DA | 1 |
| González González, D | 1 |
| Miralbell, R | 1 |
| Mornex, F | 1 |
| Greiner, R | 1 |
| Bolla, M | 1 |
| Storme, G | 1 |
| Hulshof, M | 1 |
| Bernier, J | 1 |
| Denekamp, J | 1 |
| Rojas, AM | 1 |
| Pierart, M | 1 |
| van Glabbeke, M | 1 |
| Mirimanoff, RO | 2 |
| Sun, LQ | 1 |
| Coucke, PA | 1 |
| Buchegger, F | 1 |
| Coper, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Dose Finding Study of Sorafenib in Combination With Radiation Therapy and Temozolomide as a First Line Treatment of Patients With High Grade Glioma[NCT00884416] | Phase 1 | 17 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Phase 2 Study of Sorafenib Plus Protracted Temozolomide in Recurrent Glioblastoma Multiforme[NCT00597493] | Phase 2 | 32 participants (Actual) | Interventional | 2007-09-30 | Completed | ||
| A Phase II Trial of Concurrent Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib in the First-Line Treatment of Patients With Glioblastoma Multiforme[NCT00544817] | Phase 2 | 47 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme[NCT00445588] | Phase 2 | 56 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of participants surviving six months from the start of study treatment without progression of disease. PFS was defined as the time from the date of study treatment initiation to the date of the first documented progression according to the Macdonald criteria, or to death due to any cause. (NCT00597493)
Timeframe: 6 months
| Intervention | percentage of patients (Number) |
|---|---|
| Sorafenib + Temozolomide | 9.4 |
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. AUC-24 refers to area under the plasma concentration-time curve from 0 to 24 hours. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAEDs) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months
| Intervention | ug*H/L (Geometric Mean) |
|---|---|
| EIAEDs-Day 1 | 45309.7 |
| EIAEDs-Day 28 | 47148.2 |
| Non-EIAEDs-Day 1 | 45238.7 |
| Non-EIAEDs-Day 28 | 128820.8 |
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. C-max refers to maximum plasma concentration. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months
| Intervention | ug/L (Geometric Mean) |
|---|---|
| EIAEDs-Day 1 | 3397.3 |
| EIAEDs-Day 28 | 3813.9 |
| Non-EIAEDs-Day 1 | 3155.1 |
| Non-EIAEDs-Day 28 | 8118.8 |
Blood sampling for sorafenib pharmacokinetics was performed on days 1 and 28 of cycle 1 and was obtained before and at 0.5, 1, 2, 4, 6, 8, and 24 h after the morning dose. T-max refers to time to maximum concentration. The pharmacokinetics of those patients taking enzyme-inducing antiepileptic drugs (EIAED) and those who were not were analyzed separately. (NCT00597493)
Timeframe: 13 months
| Intervention | hours (Median) |
|---|---|
| EIAEDs-Day 1 | 8.2 |
| EIAEDs-Day 28 | 2.1 |
| Non-EIAEDs-Day 1 | 24.0 |
| Non-EIAEDs-Day 28 | 4.2 |
Number of participants experiencing a toxicity of at least grade 3 that was deemed possibly, probably, or definitely related to the treatment. (NCT00597493)
Timeframe: 16 months
| Intervention | participants (Number) |
|---|---|
| Sorafenib + Temozolomide | 19 |
"The number of patients with complete or partial responses measured from the time of initial response to documented tumor progression. Radiologic response was defined using the Macdonald criteria.~The Macdonald criteria divides response into 4 types of response based on imaging (MRI) and clinical features, as follows: 1) complete response (CR); 2) partial response (PR); 3) stable disease (SD); and 4) progression (PD).~Criteria:~CR: disappearance of all enhancing disease (measurable and non-measurable) sustained for at least 4 weeks, no new lesions. No corticosteroids, clinically stable or improved.~PR: >=50% decrease of all measurable enhancing lesions, sustained for at least 4 weeks, no new lesions. Stable or reduced corticosteroids, clinically stable or improved.~SD: does not qualify for complete response, partial response or progression. Clinically stable.~PD: >= 25% increase in enhancing lesions, any new lesions. Clinical deterioration." (NCT00544817)
Timeframe: every 8 weeks until disease progression, estimated 18 months
| Intervention | participants (Number) |
|---|---|
| Combination Therapy | 13 |
Defined as Day 1 of protocol treatment to date of death from any cause. (NCT00544817)
Timeframe: 18 months
| Intervention | Months (Median) |
|---|---|
| Combination Therapy | 12 |
Defined as the duration of time from start of treatment to time of progression or death, whichever comes first. (NCT00544817)
Timeframe: 18 months
| Intervention | Months (Median) |
|---|---|
| Combination Therapy | 6 |
defined patient started treatment is alive and progression free at the time of 26-week (6 months) follow-up (NCT00445588)
Timeframe: At 6 months- defined as patient started treatment is alive and progression free at the time of 26-week (6 months) follow-up
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment | 14 |
death. measured by time of first day of treatment until date of death, assessed up to 2 years. (NCT00445588)
Timeframe: Time of first day of the treatment to death, assessed up to 2 years
| Intervention | months (Median) |
|---|---|
| Treatment | 5.7 |
1 review available for niacinamide and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizu | 2013 |
12 trials available for niacinamide and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2013 |
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dac | 2014 |
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bra | 2011 |
Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benz | 2010 |
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Femal | 2012 |
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; E | 2013 |
Radiotherapy and chemotherapy with or without carbogen and nicotinamide in inoperable biopsy-proven glioblastoma multiforme.
Topics: Adult; Aged; Biopsy; Brain; Brain Neoplasms; Carbon Dioxide; Chi-Square Distribution; Combined Modal | 2003 |
Tolerance of nicotinamide and carbogen with radiation therapy for glioblastoma.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Aged; Animals; Carbon Dioxide; | 1996 |
Lack of perfusion enhancement after administration of nicotinamide and carbogen in patients with glioblastoma: a 99mTc-HMPAO SPECT study.
Topics: Analysis of Variance; Brain Neoplasms; Carbon Dioxide; Cell Hypoxia; Cerebrovascular Circulation; Gl | 1998 |
Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933.
Topics: Administration, Inhalation; Administration, Oral; Adult; Aged; Brain Neoplasms; Carbon Dioxide; Cell | 1999 |
[Studies of the NAD(P) glycohydrolase activity in human brain tumors].
Topics: Adenoma, Chromophobe; Astrocytoma; Brain Neoplasms; Clinical Trials as Topic; Enzyme Induction; Epen | 1967 |
21 other studies available for niacinamide and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Ca
Topics: Antineoplastic Agents; Apoptosis; Astrocytes; Cell Line, Tumor; Glioblastoma; Humans; Niacinamide; P | 2023 |
Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?
Topics: Administration, Intranasal; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell | 2017 |
ABCG2-mediated suppression of chlorin e6 accumulation and photodynamic therapy efficiency in glioblastoma cell lines can be reversed by KO143.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Cell Survival; Chlorophyl | 2018 |
18F-PSMA 1007 Brain PET/CT Imaging in Glioma Recurrence.
Topics: Brain; Brain Neoplasms; Fluorine Radioisotopes; Glioblastoma; Humans; Magnetic Resonance Imaging; Ma | 2020 |
Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas.
Topics: Antineoplastic Agents; Apoptosis; Astrocytoma; Autophagy; Cell Line, Tumor; Drug Therapy, Combinatio | 2014 |
Sorafenib and lithium chloride combination treatment shows promising synergistic effects in human glioblastoma multiforme cells in vitro but midkine is not implicated.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyt | 2014 |
Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.
Topics: Anoikis; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; bcl-X Pr | 2015 |
Telomerase inhibition improves tumor response to radiotherapy in a murine orthotopic model of human glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Disease Models, Animal; Glioblastoma; Humans; Indol | 2015 |
Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; | 2016 |
MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival | 2016 |
Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Surviv | 2016 |
Forcing tumor stem cells to an end.
Topics: Glioblastoma; Humans; Indoles; Neoplastic Stem Cells; Niacinamide; Oligonucleotides; Stem Cell Trans | 2010 |
Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3.
Topics: Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cycli | 2010 |
Sorafenib plus valproic acid for infant spinal glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Combined Modality Therapy; Extrac | 2010 |
Sorafenib exerts anti-glioma activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Benzenesulfonates; Brain Neoplasms; Cell Line, | 2010 |
Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.
Topics: Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Differentiation; Cell | 2013 |
Pharmacokinetics and tolerance of nicotinamide combined with radiation therapy in patients with glioblastoma multiforme.
Topics: Administration, Oral; Adult; Aged; Brain Neoplasms; Chromatography, High Pressure Liquid; Combined M | 1994 |
Carbogen and nicotinamide combined with unconventional radiotherapy in glioblastoma multiforme: a new modality treatment.
Topics: Administration, Inhalation; Adult; Aged; Carbon Dioxide; Combined Modality Therapy; Female; Glioblas | 1997 |
Tolerance to nicotinamide and carbogen with radiation therapy for glioblastoma.
Topics: Carbon Dioxide; Glioblastoma; Humans; Niacinamide; Oxygen; Radiation-Sensitizing Agents | 1997 |
The effect of combined nicotinamide and carbogen treatments in human tumour xenografts: oxygenation and tumour control studies.
Topics: Administration, Inhalation; Animals; Carbon Dioxide; Cell Hypoxia; Drug Combinations; Glioblastoma; | 1998 |
Fractionated irradiation combined with carbogen breathing and nicotinamide of two human glioblastomas grafted in nude mice.
Topics: Administration, Inhalation; Animals; Brain Neoplasms; Carbon Dioxide; Cell Division; Combined Modali | 2001 |